SEC Form 4 · accession 0001523672-26-000007
Latigo Biotherapeutics, Inc. · LTGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd N Smith
Director
Period of report
Aug 6, 2026
Accepted (ET)
Aug 10, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002056611
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F1 | $18.00 | Aug 6, 2026 | A | 105,542 | A | — | Aug 5, 2036 | Common Stock | 105,542 | 105,542 | D |
Explanation of responses
- F1The shares subject to this option shall vest in 36 equal monthly installments after May 30, 2026.